1R,3R-Rsl3

• 分子结构分类: 有机化合物 - 生物碱及其衍生物 - 哈马拉生物碱
• 英文名称: 1R,3R-Rsl3
• 英文别名: methyl (1R,3R)-2-(2-chloroacetyl)-1-(4-methoxycarbonylphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxylate
• 化学式: C₂₃H₂₁ClN₂O₅
• 分子量: 440.9
• InChiKey: TXJZRSRTYPUYRW-WIYYLYMNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  88.7
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• Oncogenic-RAS-signal dependent lethal compounds
  申请人：Stockwell Brent R.

  公开号：US20100081654A1

  公开（公告）日：2010-04-01

  Compounds with cancer cell specific lethality are provided. In particular, RAS-selective lethal compounds and compositions are provided. Also provided are methods of screening for such compounds and methods of treating a condition in a mammal, by administering to the mammal a therapeutically effective amount of such compounds or compositions.

  提供了具有癌细胞特异性致死性的化合物。特别地，提供了选择性致死RAS化合物和组合物。还提供了筛选此类化合物的方法以及通过向哺乳动物投与此类化合物或组合物的治疗有效量来治疗哺乳动物病症的方法。
• 2,3,5-trimelthyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating alpha-synucleinopathies, tauopathies, and other disorders
  申请人：PTC THERAPEUTICS, INC.

  公开号：US11174212B2

  公开（公告）日：2021-11-16

  Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of α-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.ury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof.

  本文公开了治疗或抑制选自α-突触核蛋白病、陶氏病、ALS、创伤性脑损伤和缺血再灌注相关损伤的一组疾病的方法，包括向有需要的受试者施用治疗有效量的式化合物：或其对苯二酚形式；或其溶液或水合物。
• 2,3,5-TRIMETHYL-6-NONYLCYCLOHEXA-2,5-DIENE-1,4-DIONE FOR SUPPRESSING AND TREATING ALPHA-SYNUCLEINOPATHIES, TAUOPATHIES, AND OTHER DISORDERS
  申请人：PTC THERAPEUTICS, INC.

  公开号：US20210276937A1

  公开（公告）日：2021-09-09

  Disclosed herein are methods of treating or suppressing a disorder selected from the group consisting of α-synucleinopathies, tauopathies, ALS, traumatic brain injury, and ischemic-reperfusion related injuries.ury, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of the formula: or the hydroquinone form thereof; or a solvate or hydrate thereof.
• DECREASING IMMUNE ACTIVITY THROUGH MODULATION OF POSTCELLULAR SIGNALING FACTORS
  申请人：FLAGSHIP PIONEERING INNOVATIONS V, INC.

  公开号：US20210283091A1

  公开（公告）日：2021-09-16

  The invention provides methods of decreasing immune response by inhibiting iron-dependent cellular disassembly. The decrease in immune response may be used, for example, for treatment of a disorder associated with iron-dependent cellular disassembly, including an autoimmune disorder, allergy, or an inflammatory disorder. The invention also provides screening assays for identification of compounds that inhibit iron-dependent cellular disassembly and are also immunoinhibitory agents.
• INCREASING IMMUNE ACTIVITY THROUGH MODULATION OF POSTCELLULAR SIGNALING FACTORS
  申请人：FLAGSHIP PIONEERING INNOVATIONS V, INC.

  公开号：US20210251994A1

  公开（公告）日：2021-08-19

  The invention provides methods of increasing immune response by inducing iron-dependent cellular disassembly. The increase in immune response may be used, for example, for treatment of infection or cancer. The invention also provides screening assays for identification of compounds that induce iron-dependent cellular disassembly and are also immunostimulatory agents. The invention further provides methods for identifying immunostimulatory agents produced by cells undergoing iron-dependent cellular disassembly.